Three medications represent this progression: Semaglutide (single agonist, 15% average weight loss), Tirzepatide (dual agonist, 22.5% weight loss), and Retatrutide (triple agonist, 28.7% weight loss)
Kanazawa Y, Hayashi N, Mita E, et al
20,21 Based on studies of genetically modified mice, considerable progress has been made in illustrating the functions of genes such as Mecp2 (Rett syndrome), Tsc1/2 (tuberous sclerosis), Fmrp (fragile X syndrome), Pten and Shank3 (PhelanMcDermid syndrome) in several monogenetic diseases
This multi-pathway effect makes it effective for weight management in people with obesity or overweight conditions
Adding keto to this combination creates a three-way intervention that requires understanding how all three interact